Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Myeloproliferative Disorders 1

Interventions

fludarabine phosphate 58Cyclophosphamide 54Peripheral Blood Stem Cell Transplantation 49Mycophenolic Acid 39Busulfan 38Tacrolimus 37Cyclosporine 33Antilymphocyte Serum 33Whole-Body Irradiation 32Filgrastim 28Methotrexate 27Radiotherapy 20Melphalan 18Cytarabine 17fludarabine 16Etoposide 16Methylprednisolone 14ruxolitinib 11sargramostim 9Flow Cytometry 9Cyclosporins 9Cord Blood Stem Cell Transplantation 9Alemtuzumab 9thymoglobulin 8Sirolimus 8Psychiatric Rehabilitation 8Granulocyte Colony-Stimulating Factor 8Azacitidine 8merphos 7Decitabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myeloproliferative Disorders × LY2784544 × Clear all
NCT01134120 2018-04-17

A Study in Myeloproliferative Disorders

Eli Lilly and Company

Phase 1 Completed
80 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡